• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Legend Biotech Corporation (Amendment)

    2/14/23 4:05:07 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LEGN alert in real time by email
    SC 13G/A 1 d450084dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Legend Biotech Corporation

    (Name of Issuer)

    Ordinary Shares

    (Title of Class of Securities)

    52490G102

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 52490G102    13G/A    Page 2 of 6

     

      1    

      NAMES OF REPORTING PERSONS

     

      AquaPoint L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0.00% (2)

    12  

      TYPE OF REPORTING PERSON

     

      PN, FI

     

    (1)

    Pursuant to a judgment (Judgment –FSD 157 of 2021 (DDJ)) of the Grand Court of the Cayman Islands (the “Court”), Financial Services Division, 220610 In the Matter of AquaPoint L.P. – Judgment – FSD 157 of 2021 (DDJ), AquaPoint L.P. is in the process of being wound up under the supervision of joint official liquidators appointed by the Court. Accordingly, pending the completion of the liquidation, all voting and dispositive power with respect to the 30,300,000 ordinary shares for which AquaPoint L.P. is the registered owner is held by the joint official liquidators pursuant to the judgment.

    (2)

    This percentage is calculated based on 334,805,584 ordinary shares issued and outstanding as of September 13, 2022, as reported in the Issuer’s Proxy Statement furnished to the Securities and Exchange Commission under the cover of a Form 6-K on September 16, 2022.


    CUSIP No. 52490G102    13G/A    Page 3 of 6

     

      1    

      NAMES OF REPORTING PERSONS

     

      GenScript Corporation

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      407,172

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      407,172

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      407,172 (3)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0.12% (4)

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    (3)

    Pursuant to a judgment (Judgment –FSD 157 of 2021 (DDJ)) of the Grand Court of the Cayman Islands (the “Court”), Financial Services Division, 220610 In the Matter of AquaPoint L.P. – Judgment – FSD 157 of 2021 (DDJ), AquaPoint L.P. is in the process of being wound up under the supervision of joint official liquidators appointed by the Court. Accordingly, pending the completion of the liquidation, all voting and dispositive power with respect to the 30,300,000 ordinary shares for which AquaPoint L.P. is the registered owner is held by the joint official liquidators pursuant to the judgment.

    (4)

    This percentage is calculated based on 334,805,584 ordinary shares issued and outstanding as of September 13, 2022, as reported in the Issuer’s Proxy Statement furnished to the Securities and Exchange Commission under the cover of a Form 6-K on September 16, 2022.


    CUSIP No. 52490G102    13G/A    Page 4 of 6

     

    Item 1(a). Name of Issuer:

    Legend Biotech Corporation (the “Issuer”)

    Item 1(b). Address of Issuer’s Principal Executive Officers:

    2101 Cottontail Lane, Somerset, New Jersey 08873

    Item 2(a). Name of Person Filing:

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”)

     

      1.

    AquaPoint L.P. (“AquaPoint”); and

     

      2.

    GenScript Corporation

    This Statement relates to certain ordinary shares directly beneficially owned by GenScript Corporation. This Statement also relates to ordinary shares for which AquaPoint is the registered owner, which were previously reported as beneficially owned by AquaPoint. GenScript Corporation is the general partner of AquaPoint.

    Item 2(b). Address or Principal Business Office or, if None, Residence:

    The principal business office for AquaPoint L.P. is The R&H Trust Co. Ltd., P.O. Box 897, Windward 1, Regatta Office Park, West Bay Road, Grand Cayman, KY1-1103, Cayman Islands.

    The principal business office for GenScript Corporation is Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA.

    Item 2(c). Citizenship:

    See Item 4 of each cover page.

    Item 2(d). Title of Class of Securities:

    Ordinary shares, par value US$0.0001 per share.

    Item 2(e). CUSIP No.:

    52490G102

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c)

    Not applicable.

    Item 4. Ownership.

    Amount beneficially owned: See Item 9 of each cover page.

    Percent of class: See Item 11 of each cover page.

    Number of shares as to which each Reporting Person has:

     

      (i)

    Sole power to vote or to direct the vote: See Item 5 of each cover page.

     

      (ii)

    Shared power to vote or to direct the vote: See Item 6 of each cover page.

     

      (iii)

    Sole power to dispose or to direct the disposition of: See Item 7 of each cover page.

     

      (iv)

    Shared power to dispose or to direct the disposition of: See Item 8 of each cover page.


    CUSIP No. 52490G102    13G/A    Page 5 of 6

     

    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☒.

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

    Item 8. Identification and Classification of Members of the Group.

    Not applicable.

    Item 9. Notice of Dissolution of Group.

    Not applicable.

    Item 10. Certifications.

    Not applicable.


    CUSIP No. 52490G102    13G/A    Page 6 of 6

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2023     AquaPoint L.P.
        By: GenScript Corporation, its general partner
        By:  

    /s/ Fangliang Zhang

        Name:   Fangliang Zhang
        Title:   Authorized Signatory
        GenScript Corporation
        By:  

    /s/ Fangliang Zhang

        Name:   Fangliang Zhang
        Title:   Authorized Signatory
    Get the next $LEGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LEGN

    DatePrice TargetRatingAnalyst
    2/12/2026$24.00Buy → Neutral
    Rothschild & Co Redburn
    1/22/2026$21.00Buy → Hold
    TD Cowen
    1/7/2026$75.00Outperform
    Oppenheimer
    10/7/2025$40.00Overweight
    Cantor Fitzgerald
    10/8/2024$86.00Buy
    Redburn Atlantic
    6/17/2024$88.00Buy
    Truist
    5/24/2024$86.00 → $73.00Buy
    H.C. Wainwright
    5/23/2024$60.00Buy
    Deutsche Bank
    More analyst ratings

    $LEGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use

    Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence SOMERSET, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will present six poster presentations featuring data on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) at the Tandem Meetings of ASTCT® and CIBMTR®, taking place February 4-7, 2026, in Salt Lake City, UT. With more than 10,000 patients treated worldwide, CARVYKTI® continues to generate a growing body of clinical and real-world evidence, informing how the therapy can be op

    1/21/26 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference

    Exceeded 10,000 patients treated to date with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy manufacturing facility in the U.S.Profitability expected in 2026, driven by continued CARVYKTI® revenue growth and operating margin expansion Treated first patient with in vivo pipeline candidate in investigator-initiated trial Preclinical data from primates provided early validation for CD20/CD19 dual-targeting in vivo CAR-T cell therapy for non-Hodgkin lymphoma SOMERSET, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a g

    1/12/26 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference

    SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will present the latest company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14th, 2026, at 9:00 a.m. PT. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend's website. The webcast replay will be available approximately 48 hours after the webcast. ABOUT LEGEND BIOTECH  With over 2,900 employees, Legend Biotech is the largest standalo

    12/17/25 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Legend Biotech downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Legend Biotech from Buy to Neutral and set a new price target of $24.00

    2/12/26 7:23:25 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech downgraded by TD Cowen with a new price target

    TD Cowen downgraded Legend Biotech from Buy to Hold and set a new price target of $21.00

    1/22/26 8:26:15 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Legend Biotech with a new price target

    Oppenheimer initiated coverage of Legend Biotech with a rating of Outperform and set a new price target of $75.00

    1/7/26 8:37:12 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGN
    SEC Filings

    View All

    SEC Form 6-K filed by Legend Biotech Corporation

    6-K - Legend Biotech Corp (0001801198) (Filer)

    2/6/26 4:00:03 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Legend Biotech Corporation

    SCHEDULE 13G/A - Legend Biotech Corp (0001801198) (Subject)

    2/5/26 1:28:06 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Legend Biotech Corporation

    6-K - Legend Biotech Corp (0001801198) (Filer)

    1/23/26 8:00:07 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGN
    Leadership Updates

    Live Leadership Updates

    View All

    Legend Biotech Appoints Carlos Santos as Chief Financial Officer

    SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025. Mr. Santos is a seasoned finance executive who has led financial operations in the pharmaceutical and technology sectors across the United States, Latin America, Europe, the Middle East, and Africa. At Legend, he will oversee financial operations to work to ensure a robust balance sheet and achieve and maintain profitability. "On behalf

    8/18/25 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech Appoints Alan Bash as President of CARVYKTI®

    SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company's President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech's commercial, technical operations, and quality functions of the franchise. "This expansion in our leadership structure is on the heels of CARVYKTI's recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion," said Ying Huang, Ph.D., Chief Executive Officer of Leg

    11/4/24 7:30:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

    SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies. "This new facility underscores Legend's commitment to R&D, as we make key investments that will advance our pipeline and strengthen our leadership position in cell therapy innovation," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "We are excited to join the Philadelphia biotech community, a growing innovation hub and a prime location to attract top talent and strengthen our partn

    10/3/24 7:30:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

    SC 13G/A - Legend Biotech Corp (0001801198) (Subject)

    11/14/24 1:22:39 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

    SC 13G/A - Legend Biotech Corp (0001801198) (Subject)

    11/12/24 10:32:10 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Legend Biotech Corporation (Amendment)

    SC 13G/A - Legend Biotech Corp (0001801198) (Subject)

    4/5/24 12:18:27 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGN
    Financials

    Live finance-specific insights

    View All

    Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights

    CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 millionEC and U.S. FDA label updates for CARVYKTI® to include overall survival benefit versus standard of care Over 9,000 patients treated to dateInitiated CARVYKTI® commercial production at Tech Lane facility in BelgiumCash and cash equivalents, and time deposits of approximately $1.0 billion, as of September 30, 2025 SOMERSET, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today reported its third quarter 2025 unaudited financial results and key corporate highlights. "CARVYKTI continues to deliver strong sequential r

    11/12/25 7:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

    SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentations section approximately two

    10/29/25 8:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights

    CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 millionCARVYKTI® demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third of patients remaining progression-free for ≥5 yearsPresented other important CARVYKTI® and new solid tumor data at ASCOOver 7,500 patients treated to dateCash and cash equivalents, and time deposits of $1.0 billion, as of June 30, 2025 SOMERSET, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2025 unaudited financial results and key corporate highlights. "The groundbreaking five-yea

    8/11/25 7:00:00 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care